Utility of the ESPGHAN Biopsy-Sparing Guidelines for Celiac Disease in Children.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40071774.
- Also identified by DOI 10.14309/ajg.0000000000003402.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this study was to determine the applicability of European society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN's) biopsy-sparing approach in diagnosis of celiac disease (CD). Charts of patients who had celiac serologies and duodenal biopsies were reviewed. Sensitivity and specificity for diagnosis of CD at different cutoffs for tissue transglutaminase immunoglobulin A were assessed. Prevalence of CD was 9%. Tissue transglutaminase immunoglobulin A >10× upper level of normal has a high specificity, positive predictive value, and negative predictive value for diagnosis of CD. This study demonstrates that the criteria of ESPGHAN are reliable in diagnosing CD at our institution. Further studies are needed to determine the utility of this approach in the United States.
Medical subject headings
- Celiac Disease
- Transglutaminases
- Duodenum
- Practice Guidelines as Topic
- Immunoglobulin A